多柔比星脂质体膀胱灌注预防膀胱癌术后复发的临床研究

Clinical study of intravesical instillation of Doxorubicin Liposomes in the prevention of postoperative recurrence of bladder cancer

目的探讨多柔比星脂质体进行膀胱灌注预防膀胱癌术后复发的疗效及安全性。方法选取2013年2月～2015年3月我院收治的75例浅表性膀胱癌电切术后患者作为研究对象,按照手术先后的单双号顺序依次将其分为对照组(37例)与治疗组(38例)。对照组患者采用吡柔比星膀胱灌注,治疗组患者采用多柔比星脂质体膀胱灌注,比较两组患者的复发率及不良反应总发生率。结果随访2年,治疗组患者治疗后24个月的复发率为18.42%,低于对照组的35.14%,差异有统计学意义(P<0.05)。治疗组患者的不良反应总发生率为26.31%,低于对照组的62.16%,差异有统计学意义(P<0.05)。结论多柔比星脂质体膀胱内灌注预防膀胱癌术后复发的疗效满意。

Objective To investigate the efficacy and safety of Doxorubicin Liposome in the prevention of postoperative recurrence of bladder cancer by intravesical instillation.Methods A total of 75 patients with superficial bladder cancer who were treated in our hospital from February 2013 to March 2015 were selected as the study subjects.They were divided into the control group(37 cases)and the treatment group(38 cases)according to the sequential order of surgery.The control group was given Pirarubicin bladder infusion,and the treatment group was given Doxorubicin Liposome bladder infusion method.The recurrence rate and the total incidence rate of adverse reactions were compared between the two groups.Results The follow-up period was 2 years.The recurrence rate 24 months after treatment in the treatment group was 18.42%,which was lower than that in the control group(35.14%),and the difference was statistically significant(P<0.05).The total incidence rate of adverse reactions in the treatment group was 26.31%,which was lower than that in the control group(62.16%),and the difference was statistically significant(P<0.05).Conclusion Intravesical instillation of Doxazosin Liposomes is effective in the prevention of postoperative recurrence of bladder cancer.